A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...
Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...
The ability of immune cells-particularly CD8 + T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...
In a study published in Nature Aging on Nov. 26, a research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed that aging specifically impairs ...
IL-2 is clinically validated as an immunotherapeutic, but its use is limited by toxicity issues. AZD-6750 is an approach from Astrazeneca plc that applies cis-guiding to deliver a modified IL-2 mutein ...
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
CD8+ T cells accumulate in atherosclerotic plaques. Researchers identify a crucial signaling pathway -- with therapeutic potential. CD8+ T cells accumulate in atherosclerotic plaques. LMU researchers ...
Researchers at the Max Delbrück Center and the University of Oxford have found that a cellular housekeeping function called autophagy—by which cell components are broken down and recycled—plays a ...
Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...
Study uncovers a pathogenic subset of memory T-cells that promote tissue inflammation and highlights a potential target for treating nasal polyps and other inflammatory airway diseases. Study: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results